Craig Gedye

7.4k total citations · 1 hit paper
101 papers, 3.0k citations indexed

About

Craig Gedye is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Craig Gedye has authored 101 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Craig Gedye's work include Renal cell carcinoma treatment (22 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Cancer Genomics and Diagnostics (18 papers). Craig Gedye is often cited by papers focused on Renal cell carcinoma treatment (22 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Cancer Genomics and Diagnostics (18 papers). Craig Gedye collaborates with scholars based in Australia, Canada and United States. Craig Gedye's co-authors include Anthony J. Kettle, Christine C. Winterbourn, Laurie Ailles, Ian D. Davis, Maries van den Broek, Jacob Levine, Karīna Siliņa, Carola H. Ries, Michael Stadler and Dana Pe’er and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Craig Gedye

97 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Immune Atlas of Clear Cell Renal Cell Carcinoma

2017 694 citations Laurie Ailles, Craig Gedye et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig Gedye Australia	28	1.2k	1.0k	953	852	450	101	3.0k
Cody J. Peer United States	33	1.5k 1.2×	1.8k 1.7×	626 0.7×	559 0.7×	351 0.8×	156	4.0k
Sarah Danson United Kingdom	31	2.2k 1.8×	1.7k 1.6×	668 0.7×	1.1k 1.3×	485 1.1×	120	4.4k
Ting Xu China	31	1.2k 1.0×	968 1.0×	614 0.6×	971 1.1×	472 1.0×	175	3.6k
Judy R. van Beijnum Netherlands	29	1.2k 1.0×	1.8k 1.8×	695 0.7×	497 0.6×	721 1.6×	53	3.6k
Yan Gong China	33	627 0.5×	1.8k 1.8×	504 0.5×	654 0.8×	639 1.4×	160	3.3k
Trivadi S. Ganesan India	32	1.2k 1.0×	1.7k 1.7×	529 0.6×	365 0.4×	590 1.3×	166	3.8k
David Propper United Kingdom	24	1.3k 1.1×	1.1k 1.1×	662 0.7×	374 0.4×	532 1.2×	78	3.1k
Wolfram E. Samlowski United States	34	1.6k 1.3×	1.5k 1.4×	848 0.9×	680 0.8×	349 0.8×	154	3.7k
Jianxin Xue China	29	815 0.7×	796 0.8×	347 0.4×	787 0.9×	427 0.9×	143	2.3k
John F. Gerecitano United States	28	1.9k 1.6×	2.2k 2.1×	1.1k 1.2×	742 0.9×	358 0.8×	101	5.4k

Countries citing papers authored by Craig Gedye

Since Specialization

Citations

This map shows the geographic impact of Craig Gedye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig Gedye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig Gedye more than expected).

Fields of papers citing papers by Craig Gedye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig Gedye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig Gedye. The network helps show where Craig Gedye may publish in the future.

Co-authorship network of co-authors of Craig Gedye

This figure shows the co-authorship network connecting the top 25 collaborators of Craig Gedye. A scholar is included among the top collaborators of Craig Gedye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig Gedye. Craig Gedye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).

Frangou, Eleni, Grant D. Stewart, Ian D. Davis, et al.. (2025). LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL. Annals of Oncology. 36. S1635–S1635.

Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.

Saad, Fred, Andrew J. Armstrong, Karina Vianna, et al.. (2024). Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. European Urology Oncology. 7(6). 1394–1402. 7 indexed citations

Gedye, Craig, Carole A. Harris, Martin R. Stockler, et al.. (2023). 1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Annals of Oncology. 34. S1014–S1014.

Faulkner, Sam, Phillip Jobling, Robert A. Rush, et al.. (2023). ProNGF Expression and Targeting in Glioblastoma Multiforme. International Journal of Molecular Sciences. 24(2). 1616–1616. 5 indexed citations

Faulkner, Sam, et al.. (2023). The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma. Cancers. 15(9). 2514–2514. 5 indexed citations

Emmett, Louise, Shalini Subramaniam, Megan Crumbaker, et al.. (2023). LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology. 34. S1325–S1325. 7 indexed citations

Sternberg, Cora N., Yohann Loriot, Ernest Choy, et al.. (2023). Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).. Journal of Clinical Oncology. 41(16_suppl). 4569–4569. 1 indexed citations

10.

Faulkner, Sam, et al.. (2023). Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy. FASEB BioAdvances. 5(5). 211–220. 6 indexed citations

11.

Kong, Benjamin Y., Hao‐Wen Sim, Elizabeth H Barnes, et al.. (2022). Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma. BMJ Open. 12(9). e058107–e058107. 4 indexed citations

12.

Armstrong, Andrew J., Antoine Thiery-Vuillemin, Neal D. Shore, et al.. (2022). 1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial. Annals of Oncology. 33. S1168–S1168. 6 indexed citations

13.

Khasraw, Mustafa, Michael Weller, David Lorente, et al.. (2021). Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma. Neuro-Oncology Advances. 3(1). vdab058–vdab058. 18 indexed citations

14.

Emmett, Louise, Shalini Subramaniam, Anthony M. Joshua, et al.. (2021). ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration‐resistant prostate cancer treated with enzalutamide (ANZUP 1901). British Journal of Urology. 128(5). 642–651. 27 indexed citations

15.

Khasraw, Mustafa, Kerrie L. McDonald, Sonia Yip, et al.. (2018). ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer. Asia-Pacific Journal of Clinical Oncology. 14. 196–196. 1 indexed citations

16.

Tognela, Annette, Paul Haber, Martin R. Stockler, et al.. (2018). Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open. 8(9). e020745–e020745. 19 indexed citations

17.

Rush, Amanda, Lise Matzke, Simon Cooper, et al.. (2018). Research Perspective on Utilizing and Valuing Tumor Biobanks. Biopreservation and Biobanking. 17(3). 219–229. 27 indexed citations

18.

Gedye, Craig, Jalna Meens, Elzbieta Hyatt, et al.. (2016). Cancer stem cells are underestimated by standard experimental methods in clear cell renal cell carcinoma. Scientific Reports. 6(1). 25220–25220. 18 indexed citations

19.

John, Thomas, Michael A. Black, Tumi Toro, et al.. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clinical Cancer Research. 14(16). 5173–5180. 44 indexed citations

20.

Ebert, Lisa M., Bee Shin Tan, Judy Browning, et al.. (2008). The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research. 68(8). 3001–3009. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact